1. Home
  2. ZYME vs HAFC Comparison

ZYME vs HAFC Comparison

Compare ZYME & HAFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • HAFC
  • Stock Information
  • Founded
  • ZYME 2003
  • HAFC 1982
  • Country
  • ZYME United States
  • HAFC United States
  • Employees
  • ZYME N/A
  • HAFC N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • HAFC Major Banks
  • Sector
  • ZYME Health Care
  • HAFC Finance
  • Exchange
  • ZYME Nasdaq
  • HAFC Nasdaq
  • Market Cap
  • ZYME 751.6M
  • HAFC 774.8M
  • IPO Year
  • ZYME 2017
  • HAFC 1996
  • Fundamental
  • Price
  • ZYME $15.39
  • HAFC $25.65
  • Analyst Decision
  • ZYME Buy
  • HAFC Buy
  • Analyst Count
  • ZYME 5
  • HAFC 6
  • Target Price
  • ZYME $19.00
  • HAFC $22.63
  • AVG Volume (30 Days)
  • ZYME 572.6K
  • HAFC 251.6K
  • Earning Date
  • ZYME 10-31-2024
  • HAFC 10-22-2024
  • Dividend Yield
  • ZYME N/A
  • HAFC 3.90%
  • EPS Growth
  • ZYME N/A
  • HAFC N/A
  • EPS
  • ZYME N/A
  • HAFC 2.08
  • Revenue
  • ZYME $62,199,000.00
  • HAFC $232,767,000.00
  • Revenue This Year
  • ZYME $30.09
  • HAFC N/A
  • Revenue Next Year
  • ZYME N/A
  • HAFC $11.40
  • P/E Ratio
  • ZYME N/A
  • HAFC $12.33
  • Revenue Growth
  • ZYME N/A
  • HAFC N/A
  • 52 Week Low
  • ZYME $7.80
  • HAFC $14.45
  • 52 Week High
  • ZYME $17.70
  • HAFC $26.30
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 55.74
  • HAFC 68.06
  • Support Level
  • ZYME $12.39
  • HAFC $25.06
  • Resistance Level
  • ZYME $17.70
  • HAFC $26.07
  • Average True Range (ATR)
  • ZYME 0.84
  • HAFC 0.76
  • MACD
  • ZYME 0.10
  • HAFC 0.11
  • Stochastic Oscillator
  • ZYME 56.50
  • HAFC 84.81

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. Hanmi also offers trade-finance products. The bank has several lending offices outside California and plans to expand outside the state mainly through acquisitions. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

Share on Social Networks: